ZyVersa Therapeutics, Inc. (ZVSA)

NASDAQ: ZVSA · IEX Real-Time Price · USD
0.575
-0.016 (-2.74%)
At close: Apr 22, 2024, 4:00 PM
0.580
+0.005 (0.89%)
After-hours: Apr 22, 2024, 7:59 PM EDT
-2.74%
Market Cap 4.37M
Revenue (ttm) n/a
Net Income (ttm) -106.25M
Shares Out 7.59M
EPS (ttm) -108.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 241,317
Open 0.604
Previous Close 0.591
Day's Range 0.550 - 0.604
52-Week Range 0.500 - 90.650
Beta 0.58
Analysts Strong Buy
Price Target 12.00 (+1,987.68%)
Earnings Date May 10, 2024

About ZVSA

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory d... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ZVSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ZVSA stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(1,987.68% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide. The published data s...

18 days ago - GlobeNewsWire

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024. Inflammasome ASC Inhibitor IC 100 preclinical program...

4 weeks ago - GlobeNewsWire

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

Phase 2a trial is on track to begin in the first half of 2024. Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration syst...

5 weeks ago - GlobeNewsWire

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.

5 weeks ago - GlobeNewsWire

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

WESTON, Fla., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the tr...

7 weeks ago - GlobeNewsWire

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation.

7 weeks ago - GlobeNewsWire

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation...

2 months ago - GlobeNewsWire

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease

2 months ago - GlobeNewsWire

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.

2 months ago - GlobeNewsWire

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).

2 months ago - GlobeNewsWire

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease

Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer's Disease (AD). ZyVersa is developing IC 100, a monoclonal antibody t...

3 months ago - GlobeNewsWire

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function, independence, personality, quality of life, and significantly increa...

3 months ago - GlobeNewsWire

ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access

WESTON, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...

3 months ago - GlobeNewsWire

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

WESTON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...

3 months ago - GlobeNewsWire

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...

3 months ago - GlobeNewsWire

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P.

WESTON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...

4 months ago - GlobeNewsWire

ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200

Cholesterol Efflux Mediator TM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic kidney disease and its progression. WEST...

4 months ago - GlobeNewsWire

ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes

Plasma NLRP3 inflammasomes are significantly elevated in early-stage diabetic kidney disease, and levels progressively increase as kidney function worsens.

4 months ago - GlobeNewsWire

ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering

WESTON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing first-in-class...

4 months ago - GlobeNewsWire

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100's Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Atherosclerosis, an inflammatory disease characterized by buildup of cholesterol, lipids, and other substances (plaque) in arteries leading to heart attack and stroke, is accelerated in patients with ...

4 months ago - GlobeNewsWire

ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock

WESTON, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or the “Company”), a clinical stage specialty biopharmaceutical company developing first-in-class...

5 months ago - GlobeNewsWire

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results

Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD). Granted a...

5 months ago - GlobeNewsWire

ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract affecting 1 in 100 Americans (around 2.4 million people) that can lead to disabling bowel symptoms and ...

5 months ago - GlobeNewsWire

ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation

Despite decades of effective environmental policy and improved air quality in the US, air pollution remains the greatest environmental health risk factor, contributing to 100,000 to 200,000 incrementa...

6 months ago - GlobeNewsWire

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection

NLRP3 Inflammasome Inhibition Alleviates Neurological Impairment in the Brain of MS Mouse Model, Reinforcing Published Data for IC 100 in MS Mouse Model.

6 months ago - GlobeNewsWire